However, it is estimated that tPA is only administered to 2–6% of stroke patients because of the limited time frame in which it is effective (<4.5 hrs post initial stroke onset) and the increased risk of intracerebral hemorrhage with treatment [1], [2]. This evidence concerns the gene PLAT and Stroke.